MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
516.64%
Quick Ratio
510.06%
Cash Ratio
351.49%
Debt to Asset Ratio
105.97%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Marketable securities
    • Accounts receivable, net
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Royalty obligation - net of curr...
    • Others
Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-07-31
Cash and cash equivalents
213,768
229,342
243,497
124,304
Marketable securities
71,262
70,872
65,661
67,161
Accounts receivable, net
9,897
2,593
5,779
1,926
Inventory
4,002
3,428
458
-
Research and development tax credit receivable
7,430
6,200
1,343
561
Prepaid expenses and other current assets
7,846
7,712
8,488
11,944
Total current assets
314,205
320,147
325,226
205,896
Property and equipment, net
2,841
3,034
3,190
2,067
Right of use assets
9,421
9,825
9,096
5,165
Other assets
2,450
2,369
2,419
2,377
Total assets
328,917
335,375
339,931
215,505
Accounts payable
8,045
8,268
8,074
5,869
Accrued expenses and other current liabilities
34,022
33,897
20,767
18,971
Deferred revenue - current portion
833
-
11,512
11,413
Lease liability - current portion
1,691
1,621
1,429
2,122
Royalty obligation - current portion
16,226
13,569
3,287
-
Total current liabilities
60,817
57,355
45,069
38,375
Deferred revenue - net of current portion
21,357
11,714
-
-
Lease liability - net of current portion
10,411
10,727
9,128
4,019
Royalty obligation - net of current portion
116,583
119,063
129,707
-
Royalty obligation
-
-
-
132,321
Convertible notes
139,401
139,227
139,028
-
Total long-term liabilities
-
-
-
136,340
Total liabilities
348,569
338,086
322,932
-
Common stock, 0.001 par value 100,000,000 shares authorized at march 31, 2026 and december 31, 2025 51,237,509 and 50,900,777 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
51
51
50
50
Additional paid-in capital
773,594
767,061
762,776
760,393
Accumulated deficit
-786,181
-762,694
-739,098
-713,266
Accumulated other comprehensive loss
-7,116
-7,129
-6,729
-6,387
Total stockholders' deficit
-19,652
-2,711
16,999
40,790
Total liabilities and stockholders' deficit
328,917
335,375
339,931
215,505
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$213,768K Marketable securities$71,262K Accounts receivable, net$9,897K Prepaid expenses andother current assets$7,846K Research and developmenttax credit...$7,430K Inventory$4,002K Total current assets$314,205K Right of use assets$9,421K Property and equipment,net$2,841K Other assets$2,450K Total assets$328,917K Accumulated deficit-$786,181K Accumulated othercomprehensive loss-$7,116K Total liabilities andstockholders' deficit$328,917K Total stockholders'deficit-$19,652K Additional paid-in capital$773,594K Common stock, 0.001 parvalue 100,000,000...$51K Total liabilities$348,569K Convertible notes$139,401K Royalty obligation - netof current portion$116,583K Total currentliabilities$60,817K Deferred revenue - net ofcurrent portion$21,357K Lease liability - netof current portion$10,411K Accrued expenses andother current...$34,022K Royalty obligation -current portion$16,226K Accounts payable$8,045K Lease liability -current portion$1,691K Deferred revenue -current portion$833K

KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals, Inc. (KALV)